Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: The V-HEALTH study

Journal of Vascular Surgery

Volumn 50, Issue 6, 2009, Pages

  Conte, Michael S ^a   Nugent, Helen M ^b   Gaccione, Peter ^b   Guleria, Indira ^c   Roy Chaudhury, Prabir ^d   Lawson, Jeffrey H ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pervasis Therapeutics Inc   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ANTIGEN; PANEL REACTIVE ANTIBODY; PLACEBO;

ADULT; ALLOGENEIC AORTIC ENDOTHELIAL CELL IMPLANT; ARTERIOVENOUS ACCESS; ARTERIOVENOUS FISTULA; ARTERIOVENOUS GRAFT; ARTERY OCCLUSION; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL GRAFT; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; IMPLANT; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; THROMBOSIS; VASCULAR ACCESS; VASCULAR PATENCY; VEIN ANASTOMOSIS; WOUND INFECTION;

EID: 70549091069     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.07.108     Document Type: Article

References (42)

1. US Renal Data System. 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States (2008), National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
2. Feldman H., Kobrin S., and Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 7 (1996) 523-535
3. Beathard G.A. The treatment of vascular access graft dysfunction: a nephrologist's view and experience. Adv Renal Replace Ther 1 (1994) 131-147
4. Roy-Chaudhury P., Spergel L.M., Besarab A., Asif A., and Ravani P. Biology of arteriovenous fistula failure. J Nephrol 20 (2007) 150-163
5. Dember L.M., Beck G.J., Allon M., Delmez J.A., Dixon B.S., Greenberg A., et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 299 (2008) 2164-2171
6. Roy-Chaudhury P., Sukhatme V.P., and Cheung A.K. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 17 (2006) 1112-1127
7. Asif A., Gadalean F.N., Merrill D., Cherla G., Cipleu C.D., Epstein D.L., et al. Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int 67 (2005) 1986-1992
8. Turmel-Rodrigues L., Pengloan J., Baudin S., Testou D., Abaza M., Dahdah G., et al. Treatment of stenosis and thrombosis in hemodialysis fistulas and grafts by interventional radiology. Nephrol Dial Transplant 15 (2000) 2029-2036
9. Tordoir J.H., Rooyens P., Dammers R., van der Sande F.M., de Haan M., and Yo T.I. Prospective evaluation of failure modes in autogenous radiocephalic wrist access for hemodialysis. Nephrol Dial Transplant 18 (2003) 378-383
10. Forsten K.E., Courant N.A., and Nugent M.A. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J Cell Physiol 172 (1997) 209-220
11. Dinbergs I.D., Brown L., and Edelman E.R. Cellular response to transforming growth factor-beta1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions. J Biol Chem 271 (1996) 29822-29829
12. Kojima T., Leone C.W., Marchildon G.A., Marcum J.A., and Rosenberg R.D. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem 267 (1992) 4859-4869
13. Borrelli V., di Marzo L., Sapienza P., Colasanti M., Moroni E., and Cavallaro A. Role of platelet-derived growth factor and transforming growth factor beta1 the in the regulation of metalloproteinase expressions. Surgery 140 (2006) 454-463
14. Roy-Chaudhury P., Kelly B.S., Narayana A., Desai P., Melhem M., Munda R., et al. Hemodialysis vascular access dysfunction from basic biology to clinical intervention. Adv Renal Replace Ther 9 (2002) 74-84
15. Woods J.D., Turenne M.N., Strawderman R.L., Young E.W., Hirth R.A., Port F.K., et al. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis 30 (1997) 50-57
16. Dixon B.S., Novak L., and Fangman J. Hemodialysis vascular access survival: upper-arm native arteriovenous fistula. Am J Kidney Dis 39 (2002) 92-101
17. Zilla P., Deutsch M., Meinhart J., Puschmann R., Eberl T., Minar E., et al. Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg 19 (1994) 540-548
18. Wilson J.M., Birinyi L.K., Salomon R.N., Libby P., Callow A.D., and Mulligan R.C. Implantation of vascular grafts lined with genetically modified endothelial cells. Science 244 (1989) 1344-1346
19. Nathan A., Nugent M.A., and Edelman E.R. Tissue engineered perivascular endothelial cell implants regulate vascular injury. Proc Natl Acad Sci USA 92 (1995) 8130-8134
20. Nugent H.M., Rogers C., and Edelman E.R. Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res 84 (1999) 384-391
21. Nugent H.M., Sjin R.T., White D., Milton L.G., Manson R.J., Lawson J.H., et al. Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. J Vasc Surg 46 (2007) 548-556
22. Hughes D., Fu A.A., Puggioni A., Glockner J.F., Anwer B., McGuire A.M., et al. Adventitial transplantation of blood outgrowth endothelial cells in porcine hemodialysis grafts alleviates hypoxia and decreases neointimal proliferation through a matrix metalloproteinase-9-mediated pathway-a pilot study. Nephrol Dial Transplant 24 (2009) 85-96
23. Nugent H.M., Groothuis A., Seifert P., Guerraro J.L., Nedelman M., Mohanakumar T., et al. Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig. J Vasc Res 39 (2002) 524-533
24. US Food and Drug Administration. Points to Consider in the Characterization of Cell Lines Used to Produce Biologics (1993)
25. US Food and Drug Administration. Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues and Cellular and Tissue-based Products (HCT/Ps) (2007)
26. Sidawy A.N., Gray R., Besarab A., Henry M., Ascher E., Silva Jr. M., et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 35 (2002) 603-610
27. Gibson K.D., Gillen D.L., Caps M.T., Kohler T.R., Sherrard D.J., and Stehman-Breen C.O. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. J Vasc Surg 34 (2001) 694-700
28. Nugent M.A., Nugent H.M., Iozzo R.V., Sanchack K., and Edelman E.R. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA 97 (2000) 6722-6727
29. Nugent H.M., and Edelman E.R. Endothelial implants provide long-term control of vascular repair in a porcine model of arterial injury. J Surg Res 99 (2001) 228-234
30. Brevetti G., Schiano V., and Chiariello M. Endothelial dysfunction: a key to the pathophysiology and natural history of peripheral arterial disease?. Atherosclerosis 197 (2008) 1-11
31. Rask-Madsen C., and King G.L. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3 (2007) 46-56
32. Mannarino E., and Pirro M. Endothelial injury and repair: a novel theory for atherosclerosis. Angiology 59 (2008) 69S-72S
33. Zimering M.B., and Pan Z. Auto-antibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. J Clin Endocrin Metab 94 (2009) 2171-2177
34. Chhaya S.U., Vazifdar G.N., and Rajadhyaksha S.B. Panel reactive antibodies in patients with neoplasia and hematological disorders. Int J Hum Genet 4 (2004) 147-149
35. MacPherson B.R., Hammond P.B., and Maniscalco C.A. Alloimmunization to public HLA antigens in multi-transfused platelet recipients. Ann Clin Lab Sci 16 (1986) 38-44
36. Taaning E., and Skibsted L. The frequency of platelet alloantibodies in pregnant women and the occurrence and management of neonatal alloimmune thrombocytopenic purpura. Obstet Gynecol Surv 45 (1990) 521-525
37. US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. 2007 OPTN/SRTR Annual Report: Transplant Data 1997-2006 (2007), United States Department of Health and Human Services, Bethesda, MD
38. Terasaki P.I., and Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 4 (2004) 438-443
39. Halloran P.F., Wadgymar A., Ritchie S., Falk J., Solez K., and Srinivasa N.S. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 49 (1990) 85-91
40. Vo A.A., Toyoda M., Peng A., Bunnapradist S., Lukovsky M., and Jordan S.C. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 6 (2006) 2384-2390
41. Hayashi R., Huang E., and Nissenson A.R. Vascular access for hemodialysis. Nature Clin Pract 2 (2006) 504-513
42. Rotmans J.I., Pasterkamp G., Verhagen H.J., Pattynama P.M., Blankestijn P.J., and Stroes E.S. Hemodialysis access graft failure: time to revisit an unmet clinical need?. J Nephrol 18 (2005) 9-20